ES2981715T3 - Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar - Google Patents

Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar Download PDF

Info

Publication number
ES2981715T3
ES2981715T3 ES17871457T ES17871457T ES2981715T3 ES 2981715 T3 ES2981715 T3 ES 2981715T3 ES 17871457 T ES17871457 T ES 17871457T ES 17871457 T ES17871457 T ES 17871457T ES 2981715 T3 ES2981715 T3 ES 2981715T3
Authority
ES
Spain
Prior art keywords
glutamine
bmpr2
mutant
pah
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17871457T
Other languages
English (en)
Spanish (es)
Inventor
Joshua Fessel
L Roberts
James West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Application granted granted Critical
Publication of ES2981715T3 publication Critical patent/ES2981715T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17871457T 2016-11-15 2017-11-15 Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar Active ES2981715T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (1)

Publication Number Publication Date
ES2981715T3 true ES2981715T3 (es) 2024-10-10

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17871457T Active ES2981715T3 (es) 2016-11-15 2017-11-15 Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar

Country Status (9)

Country Link
US (2) US20190314302A1 (https=)
EP (2) EP4385576A3 (https=)
JP (1) JP7383285B2 (https=)
CN (1) CN110177463B (https=)
AU (1) AU2017362328B2 (https=)
ES (1) ES2981715T3 (https=)
HU (1) HUE067036T2 (https=)
PL (1) PL3541185T3 (https=)
WO (1) WO2018093936A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
EP3914077A4 (en) * 2019-01-25 2022-11-30 Vanderbilt University MITOCHONDRIAL TARGETING ISOKETAL/ISOLEVUGLANDIN SCAVENGERS
MX2022009256A (es) 2020-01-27 2022-10-07 Univ Vanderbilt Depuradores de isocetal/isolevuglandina dirigidos a la mitocondria y usos de los mismos.
CN116568300A (zh) * 2020-10-13 2023-08-08 范德比尔特大学 预防肾损伤破坏肠淋巴管的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084910A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
JP5132109B2 (ja) * 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
PL2091530T3 (pl) * 2006-11-13 2018-01-31 Pcb Ass Inc Kompozycja hamująca aktywność oksydazy nadph
US8314015B2 (en) * 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers
WO2013142303A1 (en) * 2012-03-19 2013-09-26 Lycera Corporation Methods and compositions for detecting immune system activation
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Also Published As

Publication number Publication date
JP2019536778A (ja) 2019-12-19
US20250381155A1 (en) 2025-12-18
PL3541185T3 (pl) 2024-08-12
AU2017362328B2 (en) 2022-03-31
EP4385576A3 (en) 2024-09-04
CN110177463B (zh) 2022-03-08
WO2018093936A1 (en) 2018-05-24
EP3541185A4 (en) 2020-06-24
HUE067036T2 (hu) 2024-09-28
AU2017362328A1 (en) 2019-06-27
EP4385576A2 (en) 2024-06-19
EP3541185B1 (en) 2024-04-24
EP3541185A1 (en) 2019-09-25
US20190314302A1 (en) 2019-10-17
CN110177463A (zh) 2019-08-27
EP3541185C0 (en) 2024-04-24
JP7383285B2 (ja) 2023-11-20

Similar Documents

Publication Publication Date Title
US20250381155A1 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
US10525029B2 (en) Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
Hall et al. The not so ‘mighty chondrion’: emergence of renal diseases due to mitochondrial dysfunction
Jalan et al. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy
AU2013259526B2 (en) New methods
Yabuki et al. Oral L-citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection
TW201605434A (zh) 使用半胱胺及其衍生物治療粒腺體疾病
Gross Treatment of severe hyponatremia
Zhang et al. Ginsenoside Rg1 improves hypoxia-induced pulmonary vascular endothelial dysfunction through TXNIP/NLRP3 pathway-modulated mitophagy
JP2000504020A (ja) ＨＥＲ２／ｎｅｕを過剰発現するガン細胞の化学療法剤に対する感作
US20070248689A1 (en) Copper lowering treatment of inflammatory and fibrotic diseases
Cairns et al. Cystinosis and its treatment
US20110065674A1 (en) Methods and compositions for improving cognitive function
HK40107155A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700B (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
TWI737972B (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
Avani et al. Cystinosis: A Review
EP3914077A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers
Zhang et al. TREM2 regulates neuroinflammation by SYK-dependent inhibition of BTK activation to improve perioperative neurocognitive dysfunction
AU2003231828B2 (en) Copper lowering treatment of inflammatory and fibrotic diseases
BR112020013714B1 (pt) Compostos para tratamento e prevenção de patologias mediadas por histona extracelular
Sullivan New treatment options for cystic fibrosis
BR112016010338B1 (pt) Composição farmacêutica compreendendo um composto de diidrogenfosfato de 2-{[3,5-bis(trifluormetil)fenil]carbamoil}-4-clorofenila e uma ou mais bases de bronsted, kit compreendendo o dito composto e uso dos mesmos para tratar ou controlar edema
EA024164B1 (ru) Фармацевтическая композиция